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Specific inhibition of the cytokine, tumor necrosis factor-α (TNF), has revolutionized the
treatment of patients with several autoimmune diseases, and genetically engineered anti-
TNF antibody constructs now constitute a heavy medicinal expenditure in many countries.
Unfortunately, up to 30% of patients do not respond and about 50% of those who do
loose response with time. Furthermore, safety may be compromised by immunogenicity
with the induction of anti-drug-antibodies (ADA). Assessment of drug pharmacokinetics
and ADA is increasingly recognized as a requirement for safe and rational use of protein
drugs.The use of therapeutic strategies based on anti-TNF drug levels and ADA rather than
dose-escalation has also proven to be cost-effective, as this allows individualized patient-
tailored strategies rather than the current universal approach to loss of response. The
objective of the present article – and the accompanying article – is to discuss the reasons
for recommending assessments of circulating drug and ADA levels in patients treated with
anti-TNF biopharmaceuticals and to detail some of the methodological issues that obscure
cost-effective and safer therapies.
Keywords: anti-TNF-α biopharmaceuticals, immunogenicity, anti-drug antibodies, pharmacokinetics, pharmacody-
namics, theranostics, individualized medicine
INTRODUCTION
Treatment of patients with various immunoinflammatory diseases
has benefited considerably from the use of genetically engineered
antibodies that specifically target inflammatory cytokines and
cytokine receptors. The first example was the use of antibody con-
structs that specifically antagonize the human cytokine, tumor
necrosis factor-α (TNF). In most cases, these biopharmaceuti-
cals dramatically improve the conditions of patients with diseases
such as rheumatoid arthritis (RA) and ankylosing spondylitis,
Crohn’s disease (CD) and ulcerative colitis, psoriasis and suppu-
rative hidradenitis, and diabetic macular edema and age-related
macular degeneration of the eye (1).
The currently used anti-TNF-biopharmaceuticals include the
chimeric human/mouse mAb, infliximab (Remicade®), the human
mAbs, adalimumab (Humira®) and golimumab (Simponi®), the
mAb/Fab fragment,certolizumab pegol (Cimzia®),and the human
TNF receptor/IgG1 fusion protein, etanercept (Enbrel®), and cor-
responding recently marketed biosimilars. They all counteract the
effects initiated through TNF binding to cellular TNF-receptors.
The effects have been dramatic in a large number of patients, and
anti-TNF biopharmaceuticals now constitute one of the heaviest
medicinal expenditures in many countries.
INADEQUATE EFFECT OF TNF-ANTAGONISTS
The use of anti-TNF biopharmaceuticals has faced physicians with
a number of challenges. Apart from immunosuppression and
other side-effects, up to 50% of patients suffer loss of response
(LOR) (1–5). In these cases, physicians are left with few choices,
all based on clinical outcome. Most often they choose to inten-
sify treatment with the existing drug, or they switch to another
TNF-inhibitor or to a different class of drugs. This has several dis-
advantages. Patients with disease symptoms in the presence of oth-
erwise therapeutic drug levels are not identified (see below), and
symptoms and tissue damage continue if the new and empirically
chosen drug is also ineffective.
The mechanisms underlying LOR are usually unknown, partly
because the problem has been neglected in the past. Possible
explanations include insufficient compliance/bioavailability and
pharmacokinetic (PK) as well as pharmacodynamic (PD) issues.
One way to deal with these problems is to use therapeutics diagnos-
tics,“theranostics.” This may enable physicians to identify patients
for whom a medication or a change in medication is likely to
work. It also provides an opportunity to tailor anti-TNF therapies
according to individual needs in contrast to the currently rec-
ommended generic approach. Testings for anti-drug antibodies
(ADA) may also inform of the risk of potentially dangerous reac-
tions caused by drug immunogenicity. Finally, theranostics has the
potential to reduce the cost of these expensive therapies (6).
RATIONAL THERAPIES BASED ON PHARMACOKINETIC
EVIDENCE
There is now plenty of evidence that long-term use of biological
TNF-inhibitors benefits from knowledge of the fate of the drugs
in individual patients and whether or not a drug induces ADA (1).
Trough serum levels of drugs are surrogate PK-markers. These lev-
els vary markedly between patients, and they often differ over time
www.frontiersin.org April 2015 | Volume 6 | Article 152 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bendtzen Immunogenicity of TNF-antagonists: I. Individualized medicine
even in the same individual (7, 8). These differences depend not
only on the structure and formulation of the TNF-antagonists, and
route and frequency of administration, but also on patient charac-
teristics, for example, age, sex, weight, underlying and intercurrent
diseases, parallel medications, and individual immune responsive-
ness. If patients with LOR are monitored for circulating drug levels,
one would be able to adjust treatment intensity on the basis of
pharmaceutical evidence. In patients with low TNF-neutralizing
capacity, higher dosage or more frequent administration of the
drug would be logical, provided there are no ADA. On the other
hand, some patients with primary LOR have therapeutic or in
some cases very high drug levels, and these patients are not likely
to benefit from intensified therapy (9). Changing to another TNF-
antagonist is also likely to be ineffective, because these patients
are unresponsive despite already high anti-TNF activity in the
blood. Interestingly, the findings of supra-therapeutic concentra-
tions of drug in patients with LOR raise the question if TNF is a
pathogenetic factor in all patients with the same diagnosis (10).
Nonetheless, monitoring functionally active drugs is warranted in
patients with primary LOR because demonstration of high drug
levels, and absence of ADA, would allow early change to effective
treatment, thus saving months of useless and expensive therapies.
SAFER THERAPIES BASED ON TESTINGS FOR DRUG
IMMUNOGENICITY
Sooner or later, many patients treated with anti-TNF biophar-
maceuticals experience side-effects or LOR (11). In some cases,
LOR can be related to individual differences in bioavailability
and to mechanisms underlying inflammation in the affected tis-
sues, including infections and changes in companion therapies.
A major contributor to secondary response failure, however, is
drug immunogenicity with production of ADA that neutralizes
the drug’s TNF-antagonistic effect and/or clears the drug from
the circulation (2). In RA and CD patients, for example, half the
patients with initial response to infliximab suffer LOR at later
stages, and ADA have repeatedly been shown to associate with
LOR development. This frequency may even be a low estimate,
because the full impact of drug immunogenicity is realized only if
patients are monitored for ADA on a routine basis or every time
side-effects or treatment failure occurs. If not, as is the usual sit-
uation today, physicians will never know that ADA could be the
cause of side-effects and LOR.
It is known that trough serum levels of drug decline as soon
as ADA appears. In many cases, the drug disappears completely
as documented in RA patients treated with infliximab (Figure 1).
Investigations of RA and CD patients have also shown that low
serum levels of infliximab, adalimumab, and etanercept, and
the presence of ADA correlate with the requirement for dose
increase and therapeutic failure. Furthermore, serious side-effects
that could be mediated by drug–ADA immune complexes have
also been reported. These include infusion and allergic reactions,
serum sickness, bronchospasm, arthus reactions, and vasculitis,
some with fatal outcome (7, 12). In view of such findings, it is
notable that the majority of patients still receive TNF-antagonists
without attention to safety issues related to induction of ADA.
An important but often neglected aspect of testing-based thera-
peutic strategies is the necessity for assays to accurately and reliably
report serum levels of active drug and ADA. Assessing ADA, for
example, is generally impeded by the fact that most anti-TNF
drugs are by themselves immunoglobulin constructs, and by the
complexity of detecting antibodies against antibodies in various
binding assays; see accompanying article.
TESTING-BASED STRATEGIES FOR THERAPEUTIC GUIDANCE
Some clinicians find that there is little need to monitor drug and
ADA levels if patients are doing well on standard regimens. Some
also question the importance of ADA development because it is
not always accompanied by clinical manifestations; this, however,
may be related to the fact that it may take months from drug-
neutralization till LOR develops. The use of assays that have little
therapeutic relevance, and assays known to generate false-negative
results contribute as well; see accompanying article.
The wide use of ELISA for detection of ADA in patient serum is
perhaps the most problematic example, as this type of assay cannot
FIGURE 1 |Temporal association of circulating drug (infliximab) and ADA
levels. Trough serum levels of infliximab and anti-infliximab antibody (ADA)
were measured in 106 RA patients using radioimmunoassay. Infliximab was
administered at a dosage of 3 mg/kg. Note the step-by-step disappearance of
infliximab when ADA develop (44% of patients were ADA-positive after
6 months). With permission from Arthritis and Rheumatism (7).
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detect ADA in the presence of drug (13). Consequently, ELISA
and other assays that underestimate ADA in the circulation may
contribute to the confusion many clinicians feel regarding drug
immunogenicity. The problem has also been acknowledged by
regulatory authorities, as both the U.S. Food and Drug Administra-
tion and the European Medicines Agency require ADA-screening
before accepting therapeutic use of new biological drugs, including
biosimilars (http://www.fda.gov/downloads/Drugs/.../Guidances/
UCM192750.pdf ).
Some clinicians find it sufficient to monitor drug levels alone
(without ADA), because ADA should reflect itself in subthera-
peutic or undetectable drug levels in the circulation. This is not
prudent for the following reasons:
• there are other causes of low drug levels than ADA. These include
improper handling and storage that may cause drug aggrega-
tion, compliance problems especially when anti-TNF drugs are
administered by patients themselves, and blood sampling at the
end of longer than normal injection cycles, which, if dosage is
unaltered, result in lower than normal drug levels. Degradation
and/or elimination of drug by other factors than ADA may also
play a role.
• If physicians continue to treat a patient with a drug that has
induced ADA,possibly even with increased doses due to low drug
levels, prolonged therapy becomes both costly and ineffective; it
also increases the risk of adverse events.
• ELISA and other binding assays do not reveal the TNF-
neutralizing capacity of an anti-TNF antibody construct. Conse-
quently, high drug levels measured by ELISA may erroneously be
interpreted as“therapeutic”even in cases where there is an insuf-
ficient TNF-neutralizing activity in the circulation. This may
result from small immune complexes consisting of drug bound
to functionally monovalent ADA, or drug bound to endogenous
TNF, a situation calling for intensified rather than unaltered
anti-TNF therapy.
Assuming the use of accurate assays that mirror the in vivo con-
ditions,how might“theranostics”help physicians optimize efficacy
and safety in individual patients?
In case of LOR, one should determine if the symptoms can be
attributed to increased activity of the primary disease or to non-
inflammatory processes, for example, anatomical complications
to the original disease. Or the “new” inflammatory activity might
be due to other conditions than relapse of the primary disease, for
example infections, ischemia, etc. In case of suspected drug failure,
it is advisable to assess the serum levels of both drug and ADA to
get insight into the pharmacoimmunology at the time of LOR. A
previously proposed decision algorithm considers four principal
situations (14), see Table 1.
Therapeutically relevant cut-off levels for drug and ADA should
be determined by prior clinical validation (10, 14).
Four scenarios are shown:
1. LOR with sub-therapeutic levels of drug and no ADA. This
condition is assumed due to inadequate bioavailability and/or
PK-issues with elevated drug turn-over. The latter might be
caused by increased inflammatory load with extensive and/or
elevated expression of TNF in the affected tissues or drug-losing
enteropathy in patients with intestinal inflammation. Patients
in this group may benefit from intensified therapy with the
already administered anti-TNF medication.
2. LOR in the presence of moderate or even high circulating
TNF-neutralizing capacity. This is speculated to constitute a
Table 1 | Decision algorithm for patients with LOR to anti-TNF biopharmaceuticals.
Trough drug level Trough anti-drug antibodies (ADA) level
No Yes
Sub-therapeutic
(full compliance)
(1) Problem (3) Problem
Insufficient bioavailability and/or increased
non-ADA-mediated clearance, see below
Insufficient bioavailability caused by ADA, including pre-existing
anti-murine (Fab) IgG against IFX
Treatment Treatment
Intensify therapy Shift to another TNF-antagonist
Note: Test ADA for cross-reactivity if shifting to biosimilar
Therapeutic or
supra-therapeutic
(2) Problem (4) Problem
Inflammation Pharmacodynamic
Pharmacodynamic issue (symptoms not driven by TNF?) Non-functional ADA
No inflammation Methodological
See below False positive test
Treatment Treatment
Confirm inflammatory activity Consider testing for functionally active, i.e., drug-neutralizing ADA
Inflammation Treat as in scenario 2
Anti-TNF drugs are ineffective, shift to non-TNF targeting
therapy (surgery?)
No inflammation
Treat the underlying cause
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PD-issue originating from activation of new immunoinflam-
matory pathways that bypass TNF as a pathophysiological
factor. These patients are not likely to benefit from intensi-
fied therapy with the TNF-inhibitor already used or, indeed,
a change to another TNF-inhibitor. These patients should be
switched to a non-TNF targeting therapeutic principle.
3. LOR with drug-neutralizing ADA and inadequate TNF-
inhibition with or without increased drug clearance. As ADA
are almost always drug-specific, these patients may benefit from
switching to a different anti-TNF drug. Note that this may not
be the case with follow-on medicines (biosimilars). In these
cases, a serum sample with ADA directed against the original
TNF-antagonist should be tested for cross-reactivity against the
biosimilar intended for further therapy.
4. LOR with optimal level of drug and detectable ADA is a rare
finding. This situation may be seen when binding assays for
ADA are false-positive. It has also been seen when a high-
sensitivity binding assay such as homogeneous mobility-shift
assay (HMSA) reports low-avidity or otherwise functionally
inactive ADA. In such cases, sera should be retested using a
cell-based assay capable of detecting functionally active drug
and drug-neutralizing ADA (10). In case of unchanged find-
ings, LOR in these patients are considered as a PD-issue that
should be treated as in scenario 2.
The algorithm shown in Table 1 has been supported by other
investigators (3–5,15) and has been tested in a prospective and ran-
domized investigation of infliximab-treated CD patients with LOR
(6). Compared to the recommended escalation of drug dosage,
treatment guided by the algorithm reduced the overall treatment
costs by 50% without affecting clinical efficacy.
It is prudent to realize that the immunogenicity of biosim-
ilars may not be the same as that of the original drugs. This
is because a biosimilar, even with an aminoacid sequence iden-
tical to that of the parent drug, may possess subtle differences
for example in glycosylation and pharmaceutical formulation
that may affect immunogenicity. ADA testings in patients receiv-
ing biosimilars are therefore warranted before and after shift of
therapy.
CONCLUSION AND PERSPECTIVES
• About one-third of patients with common chronic immunoin-
flammatory diseases do not respond to anti-TNF biopharma-
ceuticals, and another one-third sooner or later experience LOR
despite ongoing therapy.
• It is well established that immunogenicity impacts therapies with
protein drugs, including TNF-inhibitors, and severe safety issues
may result from ADA development.
• PK-issues in connection with ADA development correlate with
poor outcome of anti-TNF therapies. This is associated with
drug levels that are inadequate to neutralize TNF in the
circulation and in tissues affected by the underlying disease.
• Determining optimal therapy in patients with LOR is chal-
lenging. The recommended strategy of dose escalation and, if
ineffective, change to another TNF-antagonist may take months
and increase the risk of irreversible tissue damage – and carry a
high cost.
• Monitoring circulating levels of drug and ADA provides essential
information for safe and cost-effective interventions.
• Ideally, assays should mimic the in vivo situation and report
functionality of both drugs (drug-induced TNF neutralization)
and ADA (antibody-induced drug neutralization).
• Binding assays, for example ELISA and HMSA, do not reveal
the functions of drugs and ADA, and the artificial setup of these
assays may limit their usefulness in the clinical setting.
• Screening for ADA is now required for marketing of all new
biological drugs, including biosimilars (U.S. Food and Drug
Administration and European Medicines Agency).
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